The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Depth, duration, and risk: reaching consensus in newly diagnosed myeloma
In this interview, Amrita Krishnan, MD, City of Hope, Duarte, CA, briefly reviews three abstracts presented at the 2026 ASCO Annual Meeting, commenting on the importance of depth, duration, and risk in newly diagnosed multiple myeloma (MM) and highlighting where the field has reached consensus on what matters most. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Consensus in myeloma is a difficult thing to arrive at, but I think what we do agree on is that risk stratification is important first. Next is in regards to any regimen we use in the frontline setting, we expect a deep response and ultimately a durable response. So I think those are all the things that we agree upon. We just don’t agree upon how to reach those goals...
Consensus in myeloma is a difficult thing to arrive at, but I think what we do agree on is that risk stratification is important first. Next is in regards to any regimen we use in the frontline setting, we expect a deep response and ultimately a durable response. So I think those are all the things that we agree upon. We just don’t agree upon how to reach those goals. During my presentation, I’m going to cover three abstracts. And they sort of encompass some of the changes that we’ve seen in myeloma. So one of them is the DREAMM-9 abstract. Looking at the use of belantamab as part of an upfront quadruplet regimen in a transplant-ineligible population. The second abstract I’m looking at is interesting because it speaks to the revised IMWG classification of myeloma high-risk using genomic consensus staging. And they looked at the PERSEUS trial and looked at it with the new high-risk definition and further were able to risk-stratify patients. And so it sort of looks to the future that we’re going to move beyond classical FISH as our way to stratify patients and use this new staging system. And then the last abstract was the FORTE abstract, looking at persistence of MRD, sustained MRD negativity. And I think it ties into really our definition of cure for myeloma is in part defined by sustained MRD negativity. And certainly FORTE showed that the patients who had an MRD negativity over five years, they had a 91% PFS.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
